Form 4: ANI Pharmaceuticals Director Thomas Haughey Receives Restricted Stock Award

ANI Pharmaceuticals Inc. Director Thomas Haughey has been granted 4,336 shares of common stock as a restricted stock award, vesting in May 2026.

Summary

• Director Thomas Haughey of ANI Pharmaceuticals Inc. (ANIP) acquired 4,336 shares of common stock on May 22, 2025.
• The acquisition was a restricted stock award, with a reported price of $0 per share, indicating it is likely part of compensation.
• These shares are set to vest in full on May 22, 2026.
• Following this transaction, Thomas Haughey's beneficial ownership of ANI Pharmaceuticals common stock stands at 55,862 shares.
• The transaction was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, as a Form 4.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director receiving equity compensation aligns their interests with shareholders, signaling confidence in the company's future.

Positives

• The award of restricted stock to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• Increased insider ownership can signal confidence in the company's future prospects.

Negatives

• The issuance of new shares, even as compensation, results in a minor dilution of existing shareholder equity, though this is a common practice for executive and director compensation.

Future Outlook

The restricted stock award is set to vest on May 22, 2026, indicating a future milestone for the director's equity compensation.

Industry Context

This transaction is a routine insider filing common across all industries, reflecting standard equity compensation practices for directors in publicly traded companies, including those in the pharmaceutical sector.

Related Party Transactions

• The acquisition of restricted stock by Director Thomas Haughey is a related party transaction, representing equity compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with shareholders, potentially fostering better long-term decision-making. There is minor dilution from the issuance of new shares.
• Management/Directors: Thomas Haughey receives additional equity compensation, increasing his stake in the company.

Next Steps

• The restricted stock award will vest in full on May 22, 2026.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Thomas Haughey, Restricted Stock Award, Insider Transaction, Form 4, Equity Compensation, Director Compensation, Stock Ownership